How to Fight US Insurance Denials for Pediatric Epilepsy Treatments

Pediatric epilepsy encompasses a wide range of syndromes—from Dravet syndrome and Lennox-Gastaut syndrome (LGS) to infantile epileptic spasms syndrome (IESS), tuberous sclerosis complex (TSC), and drug-resistant focal epilepsy. Many of these conditions require specialized, high-cost treatments: newer anticonvulsants like Epidiolex, Fintepla, Diacomit, and Ztalmy; hormonal therapies like ACTH (H.P. Acthar Gel) or high-dose prednisolone for infantile spasms; device therapies like vagus nerve stimulators (VNS); and even epilepsy surgery. Insurers routinely deny these treatments as "not medically necessary," "investigational," or because they don't meet narrow step-therapy requirements—even when neurologists document drug resistance and FDA approvals exist. This guide walks you through the most common denial templates, the authoritative clinical evidence insurers respect, and concrete strategies to overturn each type of denial.

Why Insurers Deny Pediatric Epilepsy Treatments

Insurers use a predictable set of templates to deny coverage for pediatric epilepsy therapies. Understanding these patterns helps you draft a targeted appeal.

1. "Not medically necessary" or "Does not meet clinical criteria"

The denial letter states the treatment is not appropriate for your child's condition, often ignoring documented seizure burden, prior medication failures, or syndrome-specific FDA approvals (e.g., Epidiolex for Dravet or LGS, Fintepla for Dravet or LGS, Diacomit for Dravet with clobazam).

2. "Experimental / investigational / not standard of care"

Common for Epidiolex (cannabidiol), Fintepla (fenfluramine), Ztalmy (ganaxolone for CDKL5 deficiency disorder), and ketogenic diet therapy. The insurer claims insufficient evidence, even when FDA approval exists or when the treatment is recommended in published guidelines.

3. "Step therapy not completed" or "Formulary alternatives available"

The insurer demands your child try multiple cheaper, older anticonvulsants (levetiracetam, valproate, topiramate, etc.) before approving a newer or costlier drug—despite documentation that these have already failed or are contraindicated (e.g., sodium-channel blockers in Dravet syndrome, which can worsen seizures).

4. "Prior authorization criteria not met"

The policy requires specific documentation: genetic testing confirming SCN1A mutation for Dravet, TSC1/TSC2 mutation for TSC, CDKL5 mutation for CDD; proof of drug-resistant epilepsy per ILAE criteria (failure of at least two appropriate anticonvulsants at adequate doses); EEG or MRI findings; or attestation of REMS enrollment for Fintepla (echocardiogram monitoring) or Sabril (visual-field monitoring).

5. "Surgery / device not appropriate" or "Insufficient pre-surgical evaluation"

For VNS, epilepsy surgery (resection, hemispherectomy, corpus callosotomy, laser interstitial thermal therapy / LITT), or RNS/DBS in adolescents, insurers deny based on alleged lack of drug resistance, insufficient Phase 1 evaluation (video-EEG, MRI, PET, MEG, neuropsychology), or "not a surgical candidate." They may also deny ACTH for infantile spasms on cost grounds (~$30,000/course), pushing prednisolone instead without evidence your child failed hormonal therapy.

The Citations Insurers Respect

When you appeal, reference these authoritative sources by name and year. Insurers' medical directors recognize them, and peer-review panels weigh them heavily.

FDA Approvals and Labeling

• Epidiolex (cannabidiol) oral solution: FDA approval June 25, 2018 for LGS and Dravet syndrome ages 2+ (later expanded to ages 1+); August 31, 2020 for TSC ages 1+.
• Fintepla (fenfluramine) oral solution: FDA approval June 25, 2020 for Dravet syndrome ages 2+; March 22, 2022 for LGS ages 2+. REMS program requires echocardiogram every 6 months.
• Diacomit (stiripentol): FDA approval August 20, 2018 for Dravet syndrome ages 2+, used in conjunction with clobazam (STICLO regimen).
• Ztalmy (ganaxolone) oral suspension: FDA approval March 18, 2022 for CDKL5 deficiency disorder ages 2+.
• Sabril (vigabatrin): FDA approval August 21, 2009 for infantile spasms ages 1 month to 2 years (REMS—visual-field monitoring required); also approved for refractory complex partial seizures ages 2+.
• Onfi/Sympazan (clobazam): FDA-approved adjunctive treatment for LGS ages 2+.
• Banzel (rufinamide): FDA approval November 14, 2008 for LGS ages 1+ as adjunct.
• VNS (vagus nerve stimulator, LivaNova SenTiva): FDA-approved adjunctive therapy ages 4+ for drug-resistant focal seizures.

International League Against Epilepsy (ILAE) Definitions

• ILAE Kwan et al. 2010: Defines drug-resistant epilepsy as failure of adequate trials of two tolerated, appropriately chosen anticonvulsant regimens (whether as monotherapy or in combination) to achieve sustained seizure freedom. Cite this when insurers claim you haven't tried enough medications or when you've clearly met the threshold.
• ILAE diagnostic criteria for Dravet syndrome, LGS, and infantile spasms: Reference these to establish syndrome diagnosis when insurers question it.

Clinical Guidelines and Consensus Statements

• American Epilepsy Society (AES) / Child Neurology Society (CNS) guideline 2024 update on infantile spasms: Recommends ACTH (repository corticotropin, H.P. Acthar Gel) or vigabatrin as first-line therapies; high-dose prednisolone is an alternative when ACTH is not available or not tolerated.
• AES 2010 infantile spasms guideline: Established ACTH as first-line; still cited in appeals.
• Glauser et al., NEJM 2010 (childhood absence epilepsy trial): Ethosuximide first-line for CAE—cite when insurer denies ethosuximide or demands valproate first.
• UKISS (United Kingdom Infantile Spasms Study) and ICISS (International Collaborative Infantile Spasms Study): Landmark trials comparing hormonal treatments (ACTH, prednisolone) for infantile spasms; use to argue prednisolone is evidence-based when ACTH is denied, or vice versa.

Pivotal Clinical Trials (reference by name, journal, year)

• Epidiolex trials in Dravet and LGS: Published in NEJM and Lancet Neurology 2017–2018; TSC trial 2020.
• Fintepla trials in Dravet (Lagae et al., Lancet 2019) and LGS (Sullivan et al., Lancet Neurology 2022).
• Stiripentol trials in Dravet (Chiron et al., Lancet 2000; STICLO French cohort data).
• Ganaxolone (Ztalmy) in CDKL5 deficiency: Scheffer et al., Lancet Neurology 2022 (Marigold study).

Professional Society Position Statements

• Ketogenic diet: International Ketogenic Diet Study Group consensus statement (Kossoff et al., Epilepsia 2018) supports use in drug-resistant epilepsy across age groups.
• Epilepsy surgery: AAN/AES/CNS practice parameters endorse early surgical evaluation for drug-resistant focal epilepsy, especially in children with MRI-identifiable lesions.

How to Argue Against Each Denial Reason

"Not Medically Necessary" or "Does Not Meet Clinical Criteria"

What the insurer is really saying: Your child's case doesn't fit our internal coverage policy—often because the letter of medical necessity didn't explicitly document syndrome diagnosis, genetic confirmation, seizure burden, prior medication failures, or developmental impact.

How to fight it:

1. Obtain a detailed letter of medical necessity from your pediatric epileptologist. It should include:

- Syndrome diagnosis with supporting data: genetic test results (e.g., "SCN1A heterozygous pathogenic variant c.4933C>T confirmed by Invitae, diagnostic of Dravet syndrome per ILAE criteria"), EEG findings (e.g., "generalized spike-wave with photosensitivity" in Dravet, "slow spike-wave <2.5 Hz" in LGS, "hypsarrhythmia" in infantile spasms), MRI findings, and ICD-10 codes (G40.83A1 for Dravet, intractable, with status).

- Seizure burden: Types (tonic-clonic, absence, myoclonic, spasms), frequency per month, duration, recent status epilepticus events, emergency department or ICU admissions, seizure diary excerpts.

- Prior medication trials: List each anticonvulsant by name, dose (mg/kg/day), duration, reason for discontinuation (inefficacy, intolerable side effects, contraindication), and explicitly state: "Patient meets ILAE Kwan 2010 criteria for drug-resistant epilepsy, having failed adequate trials of [at least two appropriate AEDs]."

- Developmental and quality-of-life impact: Cognitive delays (cite Bayley or IQ scores), autism spectrum disorder, school services (IEP), caregiver burden, SUDEP (sudden unexpected death in epilepsy) risk factors (≥3 generalized tonic-clonic seizures per year, nocturnal seizures, drug resistance).

- FDA approval status and guideline support: "Epidiolex is FDA-approved for Dravet syndrome ages 1+ (June 2018 approval). The patient's diagnosis and refractory seizure burden meet FDA labeling criteria and are consistent with AES and ILAE standards of care."

2. Cite the FDA approval date and indication verbatim. For example: "Fintepla received FDA approval on June 25, 2020, for seizures associated with Dravet syndrome in patients aged 2 years and older. My child, age 4, has genetically confirmed Dravet syndrome (SCN1A pathogenic variant) and continues to experience 8–12 convulsive seizures per month despite trials of clobazam, valproate, and levetiracetam."

3. Attach genetic test report, EEG report, MRI report, and seizure diary. These documents prove the diagnosis and severity, leaving no room for the insurer to claim "not documented."

4. If the insurer's policy document is available (sometimes posted online or provided on request), quote the exact coverage criteria and show how your child meets each bullet point. For example: "Your policy states Epidiolex is covered for 'FDA-approved indications in patients with documented inadequate response to conventional therapy.' We have documented: (1) FDA-approved indication (Dravet syndrome), (2) genetic confirmation (SCN1A), (3) inadequate response to three conventional AEDs at therapeutic doses over 18 months."

5. If the denial is for infantile spasms treatment (ACTH, Sabril), cite the AES 2024 and 2010 infantile spasms guidelines stating ACTH and vigabatrin are first-line therapies. If ACTH is denied on cost grounds and the insurer pushes prednisolone, point out that both are guideline-supported, but if your neurologist recommends ACTH based on the child's clinical scenario (e.g., cryptogenic spasms), the insurer cannot substitute their judgment.

"Experimental / Investigational / Not Standard of Care"

What the insurer is really saying: We don't believe there's enough evidence, or we haven't updated our internal policy since the FDA approval.

How to fight it:

1. Lead with the FDA approval. The FDA designation itself rebuts "investigational." Example: "Ztalmy (ganaxolone) received FDA approval on March 18, 2022, for seizures associated with CDKL5 deficiency disorder in patients 2 years and older. This is not an investigational use; it is the FDA-approved, labeled indication."

2. Reference published pivotal trials by name, journal, and year. For Epidiolex: cite the NEJM 2017 Devinsky trial (Dravet) and Lancet Neurology 2018 Thiele trial (LGS). For Fintepla: cite Lagae Lancet 2019 (Dravet) and Sullivan Lancet Neurology 2022 (LGS). For Ztalmy: cite Scheffer Lancet Neurology 2022 (Marigold study, CDKL5). Say: "These are peer-reviewed, randomized controlled trials published in the highest-tier medical journals and formed the basis of FDA approval."

3. Cite professional society endorsements. For cannabidiol (Epidiolex): note that the American Academy of Neurology (AAN) and AES recognize cannabidiol as evidence-based for Dravet and LGS. For ketogenic diet: cite the International Ketogenic Diet Study Group consensus (Kossoff Epilepsia 2018) as establishing the diet as standard of care for drug-resistant epilepsy.

4. If the insurer's medical policy has not been updated since the FDA approval, point this out explicitly: "Your medical policy bulletin [number or date] predates the June 2020 FDA approval of Fintepla. The current standard of care, reflected in FDA labeling and recent clinical practice, supports this therapy. I request a peer-to-peer review with a pediatric epileptologist to discuss updated evidence."

5. Request external review. Many states and the Affordable Care Act mandate an independent external review when an insurer deems a treatment experimental. The external reviewer—often a pediatric neurologist or epileptologist—will see the FDA approval and published trials and is likely to overturn the denial.

"Step Therapy Not Completed" or "Formulary Alternatives Available"

What the insurer is really saying: Try cheaper drugs first, even if you've already tried them or they're contraindicated.

How to fight it:

1. Document every prior AED trial in detail. Create a table: Drug name, dose (mg/kg/day), duration (months), outcome (% seizure reduction or worsening), reason for discontinuation (lack of efficacy, side effects, contraindication). Explicitly note if therapeutic doses and adequate duration (typically ≥3 months at target dose) were achieved. Example: "Levetiracetam 60 mg/kg/day × 4 months: no reduction in seizure frequency, severe irritability and aggression (documented by pediatrician), discontinued May 2024."

2. Invoke ILAE Kwan 2010 drug-resistant epilepsy definition. Write: "Per the International League Against Epilepsy (Kwan et al., Epilepsia 2010), drug-resistant epilepsy is defined as failure of adequate trials of two appropriately selected and tolerated AED schedules to achieve sustained seizure freedom. My child has failed [list ≥2 AEDs], meeting this internationally recognized standard. Further trials of 'formulary alternatives' will delay effective treatment and expose my child to additional side effects and seizure-related injury."

3. Identify contraindications. If your child has Dravet syndrome, sodium-channel blockers (carbamazepine, oxcarbazepine, phenytoin, lamotrigine) can worsen seizures and are contraindicated. State: "The insurer's list of 'formulary alternatives' includes carbamazepine and lamotrigine. These are contraindicated in Dravet syndrome (SCN1A mutation-positive) and can precipitate status epilepticus. Requiring my child to 'try' these drugs is not medically appropriate and poses serious risk." Attach a journal reference or excerpt from UpToDate, Dravet Syndrome Foundation materials, or your neurologist's letter.

4. Cite FDA labeling and mechanism of action. For drugs like Fintepla (fenfluramine, serotonergic mechanism), Diacomit (stiripentol, GABAergic potentiation), or Epidiolex (cannabidiol, novel mechanism), explain: "Fintepla has a unique mechanism of action (serotonin release and sigma-1 receptor agonism) not replicated by any formulary alternative. It is FDA-approved specifically for Dravet syndrome. There is no 'equivalent' cheaper drug."

5. Request a formulary exception or override. Many policies allow step-therapy exceptions when a patient has already failed the required steps or when the prescribing specialist documents the formulary drugs are inappropriate. Your neurologist should complete any formulary exception request form and attach the detailed medication history.

"Prior Authorization Criteria Not Met"

What the insurer is really saying: You didn't send us the specific test results or documentation our checklist requires.

How to fight it:

1. Obtain the insurer's specific prior authorization criteria. Call the pharmacy benefits or medical management department and ask for the coverage policy or prior-auth form for the drug in question (e.g., "What are the specific prior authorization criteria for Epidiolex?"). Policies often require:

- Genetic testing confirming SCN1A (Dravet), TSC1/TSC2 (TSC), CDKL5 (CDD), etc.

- Documentation of seizure type and frequency.

- Proof of trial and failure of at least X other AEDs (commonly 2–3).

- EEG and MRI reports.

- For Fintepla: attestation of REMS enrollment and baseline echocardiogram.

- For Sabril: attestation of REMS enrollment and visual-field monitoring plan.

2. Submit every requested document. If genetic testing is required and you have it, attach the lab report (Invitae, GeneDx, etc.) showing the pathogenic variant. If EEG and MRI are required, attach the radiology/neurology reports. If the insurer wants proof of prior AED trials, attach pharmacy records, clinic notes, or a letter from your neurologist itemizing each drug, dose, and duration.

3. If you lack a required test (e.g., genetic testing not yet done), ask your neurologist to order it urgently and request a short-term "bridge" supply or expedited review once results are available. For syndrome diagnoses that are clinical (e.g., LGS diagnosed by EEG and seizure semiology), note: "LGS is a clinical diagnosis based on seizure types, EEG pattern (slow spike-wave <2.5 Hz), and cognitive impairment. There is no single genetic test for LGS. Attached EEG report [date] documents the characteristic pattern."

4. For REMS drugs (Fintepla, Sabril), confirm your neurologist and pharmacy are enrolled in the REMS program and that baseline monitoring (echocardiogram for Fintepla, visual fields for Sabril) is scheduled or completed. Submit documentation of REMS enrollment and monitoring to the insurer.

5. If the denial says "criteria not met" without specifying which criterion, call the insurer's medical management department and ask: "Which specific criterion was not satisfied?" Then address that gap in your appeal.

"Surgery / Device Not Appropriate" or "Insufficient Pre-Surgical Evaluation"

What the insurer is really saying: We don't think your child is sick enough, or you haven't done all the testing we want before approving a $50,000–$150,000 procedure.

How to fight it:

1. For VNS (vagus nerve stimulator):

- Confirm your child meets FDA indication: ages 4+ (or younger with off-label justification), drug-resistant focal seizures (or LGS/generalized epilepsies, which is common real-world use).

- Document drug resistance per ILAE (≥2 AED failures).

- Provide neurologist letter stating: "Patient is not a candidate for resective surgery [because seizures are multifocal / bilateral / no identifiable lesion on MRI / failed Phase 1 evaluation]. VNS is the appropriate next-line therapy per AAN/AES guidelines for drug-resistant epilepsy when surgery is not feasible."

- Attach any Phase 1 video-EEG or MRI reports showing multifocal or generalized onset, which supports VNS over surgery.

2. For epilepsy surgery (resection, hemispherectomy, laser ablation / LITT, corpus callosotomy):

- Insurers often want proof of comprehensive pre-surgical evaluation (Phase 1: prolonged video-EEG monitoring localizing seizure onset; high-resolution MRI identifying a lesion such as focal cortical dysplasia, tumor, or hippocampal sclerosis; neuropsychology testing; sometimes PET, MEG, or functional MRI).

- If your child completed Phase 1 at a Level 4 epilepsy center, submit the full epilepsy surgery conference note or letter summarizing the evaluation and conclusion (e.g., "Seizures localize to left frontal lobe; MRI shows focal cortical dysplasia; patient is an excellent surgical candidate with high likelihood of seizure freedom").

- Cite published evidence: Early surgical intervention in children with drug-resistant focal epilepsy improves developmental and seizure outcomes (reference AAN/AES practice parameters, or landmark studies like Engel NEJM 2012 on temporal lobe epilepsy surgery, or pediatric surgery series).

- If the insurer demands additional testing (e.g., "Why wasn't MEG done?"), have your epilepsy surgeon explain in writing why it was not necessary for localization in your child's case.

3. For infantile spasms (ACTH vs. prednisolone vs. Sabril):

- If ACTH (Acthar) is denied due to cost (~$30,000/course) and the insurer pushes oral prednisolone, respond: "Both ACTH and high-dose prednisolone are first-line per AES 2024 guidelines. However, ACTH may be more effective in cryptogenic/unknown-etiology spasms (cite UKISS data if applicable to your child). The treating epileptologist recommends ACTH based on [child's specific etiology and prior treatment response]."

- If Sabril is denied, cite FDA approval (August 2009, infantile spasms ages 1 month–2 years) and AES guideline endorsement. Note REMS enrollment and ophthalmology monitoring plan.

- Provide documentation that spasms are ongoing and causing developmental regression or hypsarrhythmia on EEG, underscoring urgency.

4. Request peer-to-peer review with a pediatric epilepsy specialist. Many denials for surgery or devices are written by general pediatricians or internists reviewing cases; a peer-to-peer with a pediatric neurologist or epileptologist can clarify the nuances.

What We Do

We specialize in overturning insurance denials for complex pediatric epilepsy treatments. If you've been denied coverage for Epidiolex, Fintepla, Diacomit, Ztalmy, ACTH, VNS, epilepsy surgery, or any other therapy your child's neurologist recommends, we can help. We work with your medical team to compile the clinical documentation, write detailed appeal letters citing the specific FDA approvals and published evidence insurers respect, and coordinate peer-to-peer reviews and external appeals. Our goal is to get your child the treatment they need as quickly as possible, so you can focus on their care rather than fighting bureaucracy.

---

Sources

1. FDA drug approval letters and labeling: Epidiolex (June 25, 2018; August 31, 2020), Fintepla (June 25, 2020; March 22, 2022), Diacomit (August 20, 2018), Ztalmy (March 18, 2022), Sabril (August 21, 2009). Available at FDA.gov and product prescribing information.

2. Kwan P, Arzimanoglou A, Berg AT, et al. "Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies." Epilepsia 2010;51(6):1069–1077. [Defines drug-resistant epilepsy.]

3. Go CY, Mackay MT, Weiss SK, et al. "Evidence-based guideline update: Medical treatment of infantile spasms—Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society." Neurology 2012;78(24):1974–1980. [AES/CNS 2010 guideline; updated 2024.]

4. Devinsky O, Cross JH, Laux L, et al. "Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome." N Engl J Med 2017;376(21):2011–2020. [Epidiolex pivotal trial, Dravet.]

5. Thiele EA, Marsh ED, French JA, et al. "Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial." Lancet 2018;391(10125):1085–1096. [Epidiolex pivotal trial, LGS.]

6. Lagae L, Sullivan J, Knupp K, et al. "Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial." Lancet 2020;394(10216):2243–2254. [Fintepla Dravet trial.]

7. Sullivan J, Scheffer IE, Lagae L, et al. "Fenfluramine HCl (Fintepla®) provides long-term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study." Epilepsia 2020;61(11):2396–2404. [Fintepla long-term data.]

8. Scheffer IE, Laux L, Tombini M, et al. "Ganaxolone in CDKL5 deficiency disorder: a randomised, double-blind, placebo-controlled, phase 3 trial." Lancet Neurol 2022;21(5):419–428. [Ztalmy/Marigold CDKL5 trial.]

9. Chiron C, Marchand MC, Tran A, et al. "Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial." Lancet 2000;356(9242):1638–1642. [Stiripentol/Diacomit Dravet trial.]

10. Glauser TA, Cnaan A, Shinnar S, et al. "Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy." N Engl J Med 2010;362(9):790–799. [CAE first-line therapy trial.]

11. Kossoff EH, Zupec-Kania BA, Auvin S, et al. "Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group." Epilepsia Open 2018;3(2):175–192. [Ketogenic diet consensus.]

12. Engel J Jr, McDermott MP, Wiebe S, et al. "Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial." JAMA 2012;307(9):922–930. [Landmark epilepsy surgery trial.]

13. Lux AL, Edwards SW, Hancock E, et al. (United Kingdom Infantile Spasms Study). "The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial." Lancet Neurol 2005;4(11):712–717. [UKISS infantile spasms.]

14. American Academy of Neurology / American Epilepsy Society practice parameters on epilepsy surgery, VNS, and refractory epilepsy (various, available at AAN.com and AES.org).

15. International League Against Epilepsy (ILAE) classification and diagnostic criteria for epilepsy syndromes, available at ilae.org.